Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017
June 09, 2017 11:39 ET
|
Actelion Pharmaceuticals Ltd
Announces receipt of all regulatory approvals required to complete acquisition of Actelion ALLSCHWIL/BASEL, SWITZERLAND - 09 June 2017 - Johnson & Johnson (NYSE:JNJ) today announced that,...
Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017
June 09, 2017 11:39 ET
|
Actelion Pharmaceuticals Ltd
Announces receipt of all regulatory approvals required to complete acquisition of Actelion ALLSCHWIL/BASEL, SWITZERLAND - 09 June 2017 - Johnson & Johnson (NYSE:JNJ) today announced that,...
Actelion veröffentlicht Update zum Phase-III-Programm IMPACT mit Cadazolid bei CDAD
June 08, 2017 01:02 ET
|
Actelion Pharmaceuticals Ltd
ALLSCHWIL, SCHWEIZ - 08. Juni 2017 - Actelion Ltd gab heute ein Update zum Phase-III-Programm IMPACT zur Ermittlung der Wirksamkeit und Sicherheit des neuartigen Antibiotikums Cadazolid im...
Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
June 08, 2017 01:02 ET
|
Actelion Pharmaceuticals Ltd
ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective...
Actelion informiert über Stand der Vorbereitungen zum Start von Idorsia - Wichtige klinische Ergebnisse für Pipeline-Kandidaten von Idorsia
May 22, 2017 01:00 ET
|
Actelion Pharmaceuticals Ltd
Positive Ergebnisse einer Dosisfindungsstudie mit ACT-132577 - Kandidat für die Weiterentwicklung in Phase 3 bei therapieresistenter HypertoniePositive Sicherheitsstudie mit Cenerimod - Kandidat für...
Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
May 22, 2017 01:00 ET
|
Actelion Pharmaceuticals Ltd
Positive dose-finding results with ACT-132577 - asset to progress to Phase 3 development in resistant hypertensionPositive safety study with cenerimod - asset to progress into larger Phase 2...
Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
May 15, 2017 11:59 ET
|
Actelion Pharmaceuticals Ltd
ALLSCHWIL/BASEL, SWITZERLAND - 15 May 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that would only take effect upon closing of the transaction with Johnson &...
Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
May 15, 2017 11:59 ET
|
Actelion Pharmaceuticals Ltd
ALLSCHWIL/BASEL, SWITZERLAND - 15 May 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that would only take effect upon closing of the transaction with Johnson &...
Publication of the definitive notice of the end result of Actelion tender offer
April 27, 2017 01:01 ET
|
Actelion Pharmaceuticals Ltd
Transaction remains on track to close towards the end of the second quarter of 2017 ALLSCHWIL, SWITZERLAND - 27 April 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a...
Publication of the definitive notice of the end result of Actelion tender offer
April 27, 2017 01:01 ET
|
Actelion Pharmaceuticals Ltd
Transaction remains on track to close towards the end of the second quarter of 2017 ALLSCHWIL, SWITZERLAND - 27 April 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a...